ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective trimmed by Citigroup from $33.00 to $32.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also weighed in on ACAD. Wall Street Zen lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Citizens Jmp increased their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Bank of America upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $29.00 price objective on the stock in a research note on Wednesday, March 25th. Mizuho upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $29.00 to $35.00 in a research note on Monday, February 23rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.00.
Read Our Latest Stock Analysis on ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Price Performance
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $268.10 million during the quarter, compared to analyst estimates of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.11 EPS. Equities analysts anticipate that ACADIA Pharmaceuticals will post 0.43 EPS for the current fiscal year.
Insider Buying and Selling
In related news, EVP Mark C. Schneyer sold 3,506 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the sale, the executive vice president directly owned 66,145 shares of the company’s stock, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Jennifer J. Rhodes sold 6,950 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total transaction of $162,491.00. Following the sale, the executive vice president directly owned 7,609 shares in the company, valued at $177,898.42. This trade represents a 47.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 15,527 shares of company stock valued at $350,917. Corporate insiders own 26.20% of the company’s stock.
Institutional Trading of ACADIA Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its position in shares of ACADIA Pharmaceuticals by 25.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 658,813 shares of the biopharmaceutical company’s stock valued at $17,320,000 after buying an additional 133,393 shares during the last quarter. GSA Capital Partners LLP raised its position in shares of ACADIA Pharmaceuticals by 210.1% in the third quarter. GSA Capital Partners LLP now owns 75,902 shares of the biopharmaceutical company’s stock valued at $1,620,000 after buying an additional 51,428 shares during the last quarter. Braidwell LP acquired a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at about $50,760,000. SG Americas Securities LLC raised its position in shares of ACADIA Pharmaceuticals by 613.4% in the third quarter. SG Americas Securities LLC now owns 39,680 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 34,118 shares during the last quarter. Finally, Public Sector Pension Investment Board raised its position in shares of ACADIA Pharmaceuticals by 15.3% in the third quarter. Public Sector Pension Investment Board now owns 486,988 shares of the biopharmaceutical company’s stock valued at $10,392,000 after buying an additional 64,736 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about ACADIA Pharmaceuticals
Here are the key news stories impacting ACADIA Pharmaceuticals this week:
- Neutral Sentiment: ACADIA reported Q1 2026 earnings of $0.02 per share, below the $0.04 consensus, while revenue of $268.1 million also missed estimates. The company did still post 9.7% year-over-year revenue growth and reaffirmed its 2026 guidance. Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
- Neutral Sentiment: HC Wainwright kept a Buy rating and $37 price target, but trimmed several forward EPS estimates for ACADIA, including FY2026 to $0.37 from $0.46 and Q3 2026 to $0.13 from $0.16, reflecting a slightly more cautious outlook. Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (OtherKSPHF), Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)
- Neutral Sentiment: The firm also lowered longer-term earnings forecasts for FY2027, FY2028, FY2029 and FY2030, but the reductions were modest and the analyst still sees substantial profit growth over time.
- Negative Sentiment: The latest earnings miss and the analyst estimate cuts likely reinforce concerns that near-term profitability may be more uneven than investors expected, which can weigh on the stock. ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.
See Also
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
